enGene Holdings Inc. (NASDAQ:ENGNW) Sees Large Drop in Short Interest

enGene Holdings Inc. (NASDAQ:ENGNW) was the recipient of a significant decline in short interest in December. As of December 15th, there was short interest totaling 2,052 shares, a decline of 28.6% from the November 30th total of 2,873 shares. Based on an average trading volume of 12,801 shares, the days-to-cover ratio is presently 0.2 days. Based on an average trading volume of 12,801 shares, the days-to-cover ratio is presently 0.2 days.

enGene Stock Performance

Shares of NASDAQ:ENGNW traded down $0.14 during trading hours on Wednesday, hitting $2.96. 500 shares of the company’s stock traded hands, compared to its average volume of 11,082. The company’s fifty day simple moving average is $2.46 and its two-hundred day simple moving average is $1.45. enGene has a 52 week low of $0.51 and a 52 week high of $3.80.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.